Repaglinide and Hallucination, visual - a phase IV clinical study of FDA data

Summary:

Hallucination, visual is reported as a side effect among people who take Repaglinide (repaglinide), especially for people who are female, 60+ old, also take Prazepam, and have Encephalitis.

The phase IV clinical study analyzes which people have Hallucination, visual when taking Repaglinide. It is created by eHealthMe based on reports of 8,187 people who have side effects when taking Repaglinide from the FDA, and is updated regularly.

What is Repaglinide?

Repaglinide has active ingredients of repaglinide. It is often used in diabetes. eHealthMe is studying from 8,226 Repaglinide users. Check the latest studies of Repaglinide.

What is Hallucination, visual?

Hallucination, visual (seeing things that aren't there) is found to be associated with 1,049 drugs and 1,370 conditions by eHealthMe. Check the latest studies of Hallucination, visual.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

8,187 people reported to have side effects when taking Repaglinide.
Among them, 18 people (0.22%) have Hallucination, visual.

Could Repaglinide cause Hallucination, visual?

Among these 18 people:

What is the gender of people who have Hallucination, visual when taking Repaglinide? *

female: 72.22 %
male: 27.78 %

What is the age of people who have Hallucination, visual when taking Repaglinide? *

What are other drugs people take besides Repaglinide? *

What are other side effects people have besides Hallucination, visual? *

Confusional State: 17 people, 94.44%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 10 people, 55.56%
Constipation: 10 people, 55.56%
Speech Disorder: 5 people, 27.78%
Myoclonus (a brief, involuntary twitching of a muscle or a group of muscles): 3 people, 16.67%
Confusion: 3 people, 16.67%
Agitation (state of anxiety or nervous excitement): 2 people, 11.11%
Encephalopathy (functioning of the brain is affected by some agent or condition): 2 people, 11.11%
Weight Decreased: 2 people, 11.11%
Neurological Eyelid Disorder (disease of eyelid due to nervous system): 1 person, 5.56%

What are the existing conditions these people have? *

Stress And Anxiety: 10 people, 55.56%
Pain: 10 people, 55.56%
Osteoporosis (bones weak and more likely to break): 10 people, 55.56%
Encephalitis (inflammation of the brain): 10 people, 55.56%
Neuralgia (pain in one or more nerves): 3 people, 16.67%
Hallucinations (sensations that appear real but are created by your mind): 1 person, 5.56%
Bradycardia (abnormally slow heart action): 1 person, 5.56%
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (long lasting infection of nerves outside brain and spinal cord): 1 person, 5.56%
Depression: 1 person, 5.56%
Dyslipidaemia (abnormal amount of lipids): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Repaglinide and have Hallucination, visual?

- Check whether Hallucination, visual is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Repaglinide:

Repaglinide (8,226 reports)

Browse all side effects of Repaglinide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hallucination, visual:

Hallucination, visual (1,049 drugs)

Browse all the conditions that are associated with Hallucination, visual:

Hallucination, visual (1,370 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on repaglinide (the active ingredients of Repaglinide) and Repaglinide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.